
|Articles|October 1, 2012
SCC prevention is real target in treating actinic keratoses
Options for topical treatment of actinic keratoses (AKs) are increasing, but in choosing a management approach, dermatologists should keep in mind that AKs are a premalignant condition, and the ultimate goal of therapy is prevention of squamous cell carcinoma (SCC). Field treatment is the key to managing the entire disease, says Neal Bhatia, M.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
UCB Presents 3-Year BE HEARD Trial Results for Bimekizumab in Moderate-to-Severe HS
3
Kicking Off MOPD 2026 With Lawrence Schachner, MD
4
Sagimet and Ascletis Report Positive 52-Week Safety and Efficacy Data for Denifanstat in Acne
5











